Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Renal Denervation: Device Market’s Gold Rush

This article was originally published in Start Up

Executive Summary

Three years ago, only Ardian was publicly working on renal denervation devices for hypertension, but at last month’s ACC meeting, some said there were now anywhere from 16 to 40 companies in the space. Fast followers don’t want to miss out on an IP land grab in today’s hottest medical device space.

You may also be interested in...

Device/Diagnostics Quarterly Deal Statistics, Q4 2012

Device firms closed the final quarter of 2012 with $1.1 billion in financing, led by Volcano’s debt offering. Takeovers of Gambro and PSS Medical topped the device M&A list. At $196 million, Q4 diagnostic financing was the lowest quarter of the year, but IPOs returned with three public debuts. Amgen’s $415 million acquisition of deCODE was the largest diagnostic M&A.

Renal Denervation Land Grab Continues As Boston Scientific Buys Vessix

In the latest of a series of deals in what many industry executives and analysts consider to be the next blockbuster device product market, Boston Scientific became the third major vascular player to buy its way into the renal denervation space with its recent acquisition of Vessix Vascular for a sum that could amount to $425 million. With this deal, Boston Scientific joins Medtronic, which led the way in 2010 with its stunning potentially billion dollar acquisition of Ardian, followed earlier this year by Covidien’s acquisition of Maya Medical.

The Renal Denervation Buzz: Separating Fact From Myth

Is renal denervation the next blockbuster device technology? Judging by the excitement at the EuroPCR meeting in May, the potential is there. Just before the meeting, Covidien announced its acquisition of renal denervation start-up Maya Medical.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts